Genesys Capital News Archive

Fusion Pharmaceuticals Announces Research Collaboration with Pepscan to Develop Peptide-Based Radiopharmaceuticals

HAMILTON, ON and BOSTON, Jan. 11, 2022 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the company has entered into a strategic research collaboration with Pepscan Therapeutics B.V. (Pepscan) to discover novel, peptide-based radiopharmaceuticals for the treatment of various solid tumors....

Fusion Pharmaceuticals Announces Research Collaboration with 48Hour Discovery to Develop Peptide-Based Radiopharmaceuticals

HAMILTON, Ontario and BOSTON, Jan. 11, 2022 /CNW/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the company has entered into a strategic research collaboration with 48 Hour Discovery Inc....

Fusion Pharmaceuticals Announces Nomination of First Targeted Alpha Therapy Candidate in Collaboration with AstraZeneca to Advance into IND-Enabling Studies for Phase 1 Development

HAMILTON, Ontario and BOSTON, Jan. 10, 2022 /CNW/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced nomination of the first targeted alpha therapy (TAT) candidate under the Company's collaboration agreement with AstraZeneca (LSE/STO/Nasdaq: AZN)...

Kenneth Knudson Joins Profound Medical as Chief Commercial Officer

TORONTO, Jan. 05, 2022 (GLOBE NEWSWIRE) — Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced...

Fusion Pharmaceuticals Appoints Industry Veteran Christopher Leamon, Ph.D., As Chief Scientific Officer

HAMILTON, Ontario and BOSTON, Nov. 2, 2021 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the appointment of Christopher Leamon, Ph.D., as chief scientific officer...

Fusion Pharmaceuticals Appoints Mohit Rawat As President And Chief Business Officer

HAMILTON, ON and BOSTON, Sept. 28, 2021 - Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the appointment of Mohit Rawat as President and Chief Business Officer...

Giiant Pharma Inc. appoints Christophe Mellon, PhD as Vice President, Discovery & Chemistry

MONTREAL – Giiant Pharma Inc., a Montreal biotech company developing gut-restricted drug therapeutics at the pre-clinical stage in gastroenterology, announced the expansion of its research leadership team with the appointment of Christophe Mellon, PhD.

Inversago Pharma Initiates a Phase 1 Clinical Trial on INV-202, a Next Generation Peripherally-acting CB1 Blocker

MONTREAL (CANADA) – September 7th, 2021 – Inversago Pharma Inc. (“the Company” or “Inversago”), the peripheral CB1 blockade company, today announced that following the receipt of a No Objection Letter (NOL) from Health Canada on July 29, 2021, it has dosed the first volunteers with INV-202 in its first-in-human phase 1 clinical trial...

Fusion Pharmaceuticals And TRIUMF Announce Expanded R&D Collaboration For Actinium Supply Production

HAMILTON, ON and BOSTON and VANCOUVER, BC, Aug. 12, 2021 - Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, and TRIUMF, Canada's particle accelerator centre, today announced that the companies have entered into the next phase...

Fusion Pharmaceuticals Announces Second Quarter 2021 Financial Results And Business Update

HAMILTON, ON and BOSTON, Aug. 10, 2021 - Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced financial results for the second quarter ended June 30, 2021 and provided an update on clinical and corporate developments.

Liminal BioSciences Announces Sale of Priority Review Voucher for USD105M

LAVAL, QC and CAMBRIDGE, England , Aug. 9, 2021 - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), announced today that, its subsidiary Prometic Biotherapeutics Inc. ("PBT") has entered into a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher ("PRV") for USD105M.

Profound Medical Announces Second Quarter 2021 Financial Results

TORONTO, Aug. 04, 2021 - Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported financial results for the second quarter ended June 30, 2021.

Fusion Pharmaceuticals Announces FDA Clearance Of IND For FPI-1966, An Investigational Radiopharmaceutical For The Treatment Of Head And Neck And Bladder Cancers Expressing FGFR3

HAMILTON, ON and BOSTON, July 28, 2021 - Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines...

Giiant Pharma Inc. extended its Seed round with AQC Capital and CQDM to ensure reaching clinical proof-of-concept

MONTREAL – Giiant Pharma Inc. announced today that is closed an additional financing of $750,000 from AQC Capital (AQC) and $500,000 from CQDM for a total of $1.25 million.

Veralox Therapeutics Appoints Michael Hanna As Chief Medical Officer

FREDERICK, Md., June 23, 2021 - Veralox Therapeutics, a biotechnology company developing first-in-class small molecule therapeutics that treat the underlying pathologies of diseases with significant unmet medical needs, today announced the appointment of Michael S. Hanna, MD, FACC, as chief medical officer.

Liminal BioSciences Announces Signature of a Share Purchase Agreement for Sale of Remaining Plasma-derived Business with Kedrion

LAVAL, CANADA, and CAMBRIDGE, ENGLAND –June 23, 2021 – Liminal BioSciences Inc. (Nasdaq: LMNL) (“Liminal BioSciences” or the “Company”), announced today that, Kedrion S.p.A (“Kedrion”) has exercised its option to acquire the remainder of the Company’s plasma-derived business under the terms of the Share Purchase Agreement entered into by the Company and Kedrion...

Giiant Pharma Inc. strengthens its Board of Directors with the appointment of Dr. Marie Lindner

MONTREAL – Giiant Pharma Inc., a preclinical-stage biotech company developing gut-restricted drug therapeutics in gastroenterology, announced the appointment of a seasoned executive as an independent board member.

Veralox Therapeutics Announces Closing Of $16.6 Million Series A Financing And Announces New Board Members

Veralox Therapeutics, a biotechnology company developing first-in-class small molecule therapeutics that treat the underlying pathologies of diseases with significant unmet medical needs, today announced the closing of a $16.6 million Series A financing. The round was led by Hatteras Venture Partners with participation from Genesys Capital...

Fusion Pharmaceuticals Announces Preliminary Safety And Dosimetry Results From Its Single-Dose Portion Of The Phase 1 Study Of FPI-1434

HAMILTON, Ontario and BOSTON, June 14, 2021 - Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the presentation of preliminary Phase 1 data from the single-dose portion of the study at the Society of Nuclear Medicine and Molecular Imaging (SNMMI)...

Liminal BioSciences Announces FDA Approval for its Biologics License Application for Ryplazim® (plasminogen, human-tvmh)

LAVAL, CANADA, and CAMBRIDGE, ENGLAND –June 4, 2021 – Liminal BioSciences Inc. (Nasdaq: LMNL) (“Liminal BioSciences” or the “Company”) announced today that the U.S. Food & Drug Administration (FDA) has approved Ryplazim® (plasminogen, human-tvmh) (“Ryplazim®”) for the treatment of patients with plasminogen deficiency type 1 (hypoplasminogenemia)...

Fusion Pharmaceuticals Enters Into Agreement To Build Radiopharmaceutical Manufacturing Facility

HAMILTON, ON and BOSTON, June 2, 2021 - Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced it entered a 15-year lease agreement with Hamilton, Ontario-based McMaster University to build a 27,000 square foot...

Giiant Pharma Inc. announced the closing of US$11M in Seed financing to develop its Precision Delivery technology platform in gastroenterology.

MONTREAL – Giiant Pharma Inc., a Montreal-based preclinical-stage biotech company today announced the closing of US$11M (CAD$ 13.5M) million in Seed financing. The round was co-led by Amplitude Ventures and Genesys Capital, with participation from Fonds de solidarité FTQ, AmorChem II Fund, Theodorus Investment Funds, Anges Québec, and other angel investors.

Profound Medical Announces First Quarter 2021 Financial Results

TORONTO, May 12, 2021 - Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported financial results for the first quarter ended March 31, 2021.

Fusion Pharmaceuticals Announces First Quarter 2021 Financial Results And Business Update

HAMILTON, ON and BOSTON, May 11, 2021 - Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced financial results for the first quarter ended March 31, 2021 and provided an update on clinical and corporate developments.

Profound Medical and Akumin Enter into U.S. Multi-Center Commercial Agreement for TULSA-PRO®

TORONTO, May 06, 2021 - Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced the signing of a multi-site imaging center agreement for TULSA-PRO® with Akumin Inc...

Fusion Pharmaceuticals Announces Clinical Collaboration With Merck To Evaluate Fusion's Targeted Alpha Therapy (TAT) In Combination With Merck's KEYTRUDA® (Pembrolizumab) In Patients With Solid Tumors Expressing IGF-1R

HAMILTON, ON and BOSTON, May 6, 2021 - Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that it has entered into a clinical trial collaboration with a subsidiary of Merck (known as MSD outside the U.S. and Canada) to evaluate Fusion's lead candidate...

IDbyDNA Appoints Next-Gen Sequencing Executive Neil Gunn as New CEO

Metagenomics Innovator Expands Executive Team to Meet Growing Demand for its Actionable Infectious Disease Testing and Pathogen Surveillance Infectious disease continues to be a leading cause of illness, morbidity and mortality around the world. In the fight to better understand all pathogens, including the SARS-CoV-2 lineage and its mutations, IDbyDNA, the pioneer in Precision Metagenomics, is focused on broadening availability for its Next-Generation Sequencing (NGS) targeted products...

Profound Medical to Release First Quarter 2021 Financial Results on May 12 – Conference Call to Follow

TORONTO, April 21, 2021 - Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its first quarter 2021 financial results after market close on Wednesday, May 12, 2021.

Fusion Pharmaceuticals Announces Preclinical Combination Data Demonstrating Enhanced Efficacy In Multiple Preclinical Tumor Models

HAMILTON, ON and BOSTON, April 10, 2021 - Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the presentation of preclinical data at the 2021 American Association for Cancer Research (AACR) Virtual Annual Meeting...

Aptinyx Recommences Phase 2 Study of NYX-458 in Patients with Cognitive Impairment Associated with Parkinson’s Disease Dementia and Dementia with Lewy Bodies

EVANSTON, Ill. - Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders...

Fusion Pharmaceuticals Announces Fourth Quarter 2020 Financial Results And Business Update

HAMILTON, ON and BOSTON, March 25, 2021 - Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced financial results for the fourth quarter ended December 31, 2020 and provided an update on clinical and corporate developments.

IDbyDNA Boosts Its Global Metagenomic Respiratory Pathogen/AMR Surveillance Solution to Now Offer Enhanced SARS-CoV-2 Variant Interpretation

SAN FRANCISCO MARCH 23, 2021 - As the battle against COVID-19 rages on, virus variants that can spread more easily – or for which vaccines and treatments are less effective – pose one of the most immediate threats. The widely used PCR and rapid antigen tests cannot detect these variants, allowing the virus to evolve in stealth mode...

Profound Medical Announces the Appointment of Cynthia Lavoie to its Board of Directors

TORONTO, March 03, 2021 - Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, announced today the appointment of Cynthia Lavoie Ph.D., MBA, to its Board of Directors.

Fusion Pharmaceuticals To Expand Pipeline With Acquisition Of IPN-1087, A Small Molecule Targeting NTSR1, From Ipsen

HAMILTON, ON and BOSTON, March 2, 2021 - Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced it has entered into an asset purchase agreement (APA) to acquire Ipsen's (Euronext: IPN; ADR; IPSEY) intellectual property and assets...

Profound Medical Announces Fourth Quarter and Full Year 2020 Financial Results

TORONTO, March 02, 2021 - Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported financial results for the fourth quarter and full year ended December 31, 2020.

Flosonics Medical Closes US$14M Financing Round and Expands Board of Directors

SUDBURY, Ontario - Flosonics Medical, a Canadian medical device company focused on non-invasive hemodynamic monitoring, announced the close of a $14 million USD funding round led by Arboretum Ventures. The financing also included participation from existing investors iGan Partners and Genesys Capital...

Invitae Announces Proposed Public Offering of Common Stock

SAN FRANCISCO, Jan. 20, 2021 - Invitae Corporation (NYSE: NVTA) today announced that it has commenced an underwritten public offering of $400.0 million of shares of its common stock, before deducting underwriting discounts and commissions and other offering expenses. All of the shares are being offered by Invitae...

IDbyDNA Announces Engagement in United States Defense Advanced Research Projects Agency (DARPA) Program to Detect Threats using Gene Editing Technologies

Today, IDbyDNA, the company revolutionizing the use of metagenomics to improve health by decoding the unknown, is announcing its participation in the “Detect It with Gene Editing Technologies” (DIGET) program funded by the United States Defense Advanced Research Projects Agency (DARPA)...

CareDx Announces AlloID and Exclusive Partnership with IDbyDNA

SOUTH SAN FRANCISCO, Calif. and SALT LAKE CITY, Jan. 07, 2021 - Today, CareDx, the leading partner in transplant care, and IDbyDNA, the company revolutionizing the use of precision metagenomics, announced an exclusive partnership focused on the development of metagenomic infectious disease testing specific to transplant patients...

Inversago Pharma Receives Rare Pediatric Disease Designation from the FDA for INV-101 for the Treatment of Prader-Willi Syndrome

MONTREAL (CANADA) – January 07, 2021 – Inversago Pharma Inc. (“the Company” or “Inversago”), the peripheral CB1 blockade company, today announced the U.S. Food and Drug Administration (FDA) granted a Rare Pediatric Disease (RPD) designation to the Company’s lead compound, INV-101, for the treatment of Prader-Willi syndrome (PWS)...

Functional neuromodulation announces breakthrough device designation from the U.S. FDA for Deep Brain Stimulation for Alzheimer’s disease

MINNEAPOLIS, Jan. 6, 2021 - Functional Neuromodulation announced today that it has received Breakthrough Device designation from the Center for Devices and Radiological Health (CDRH) of the U.S. Food and Drug Administration (FDA) for the Vercise™ Deep Brain Stimulation (DBS) Systems, developed and manufactured by Boston Scientific Corporation...

Aptinyx Announces Recommencement of Phase 2 Study of NYX-2925 in Patients With Painful Diabetic Peripheral Neuropathy

EVANSTON, Ill. - Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorder today announced that in December it recommenced patient recruitment and screening in a Phase 2 study of NYX-2925...

Profound Medical Signs Agreement with GE Healthcare to Expand Provider Access to TULSA-PRO®

TORONTO, Dec. 21, 2020 - Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies which combireal-time Magnetic Resonance Imaging (“MRI”), thermal ultrasound and closed-loop temperature feedback control for the radiation-free ablation of diseased tissue...

Fusion Pharmaceuticals Initiates Multi-Dose Portion Of Phase 1 Trial Of FPI-1434 In Patients With Advanced Solid Tumors

HAMILTON, ON and BOSTON, Dec. 10, 2020 - Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals precision medicines, today announced that the first patient has been dosed in the multi-dose portion of the Phase 1 study evaluating [225Ac]-FPI-1434 (FPI-1434) in patients wiadvanced solid tumors...

Inversago Pharma continues to rapidly expand its leadership team and appoints Glenn D. Crater, MD, FCCP as Chief Medical Officer

MONTREAL (CANADA) – November 30, 2020 – Inversago Pharma Inc. (“the Company” or “Inversago”), the peripheral CB1 blockade company, today announced it has appointed Glenn D. CrateMD, FCCP as its Chief Medical Officer...

Profound Medical Receives FDA HDE Approval for Sonalleve®

TORONTO, Nov. 30, 2020 - Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”) announced today that Sonalleve® has received U.S. Food and Drug Administratio“FDA”) approval under a Humanitarian Device Exemption (“HDE”) for the treatment of osteoid osteoma.

Inversago Pharma continues to rapidly expand its leadership team and appoints Glenn D. Crater, MD, FCCP as Chief Medical Officer

MONTREAL (CANADA) – November 30, 2020 – Inversago Pharma Inc. (“the Company” or “Inversago”), the peripheral CB1 blockade company, today announced it has appointed Glenn D. Crater, MD, FCCP as its Chief Medical Officer. In this position, Dr. Crater will oversee the clinical development of Inversago’s lead compound for Prader-Willi syndrome...

Fusion Pharmaceuticals Announces Third Quarter 2020 Financial Results And Business Update

HAMILTON, ON and BOSTON, Nov. 10, 2020 - Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals precision medicines, today announced financial results for the third quarter ended September 30, 2020 and provided an update on clinical and corporate developments.

Profound Medical Announces Third Quarter 2020 Financial Results

TORONTO, Nov. 05, 2020 - Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies which combireal-time Magnetic Resonance Imaging (“MRI”), thermal ultrasound and closed-loop temperature feedback control for the radiation-free ablation of diseased tissue...

Invitae Reports $68.7 Million in Revenue Driven by 170,000 Samples Accessioned in the Third Quarter of 2020

SAN FRANCISCO, Nov. 5, 2020 - Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced financial and operating results for the third quarter endSeptember 30, 2020.

Fusion Pharmaceuticals announced a global collaboration with AstraZeneca

Fusion Pharmaceuticals (NASDAQ: FUSN), a Genesys originated company, announced a global collaboration with AstraZeneca to co-develop next generation targeted alpha radiopharmaceuticals and radiopharmaceutical combination therapies...

Inversago Pharma closes US$35M Series B Financing

MONTREAL (CANADA), September 08, 2020 - Inversago Pharma Inc. today announced it has secured a US$35 million (€32 million) Series B financing round led by Forbion, with co-investment from the Fonds de solidarité FTQ, and strong participation from existing investors Genesys Capital.

IDbyDNA and Illumina Partner to Deliver NGS Infectious Disease Solutions

SAN FRANCISCO, March 17, 2020 – IDbyDNA Inc., a metagenomics technology company setting a standard for detection, identification and interpretation of microorganisms and their role in human health, today announced a global strategic partnership with Illumina, Inc. (Nasdaq: ILMN), to bring comprehensive next-generation sequencing (NGS) based workflows to the global microbiology market....

Profound Medical Announces Positive Topline Results from TACT Pivotal Clinical Trial of TULSA-PRO® in Patients with Prostate Cancer

TORONTO, April 04, 2019 - Profound Medical Corp. (TSX:PRN; OTCQX:PRFMF), the only company to provide customizable, incision-free therapies which combine real-time Magnetic Resonance imaging (“MRI”), thermal ultrasound and closed-loop temperature feedback control...

Genesys Capital is pleased to announce the closing of the Series B financing of Genesys Ventures III portfolio company, Fusion Pharmaceuticals

Apr. 2, 2019 - At US$105 million, this is one of the largest private financings in the history of the Canadian Life Sciences sector. The round was co-led by OrbiMed Advisors and Varian Medical Systems...

Invitae More Than Doubles Annual Volume and Revenue Year-Over-Year, Delivering 117% in Revenue Growth Driven by 102% Growth in Volume in 2018

SAN FRANCISCO, Feb. 19, 2019 - Invitae Corporation (NYSE: NVTA), a leading genetics company, today announced financial and operating results for the fourth quarter and full year ended December 31, 2018...

Fusion Pharmaceuticals Announces First Patient Dosing In A Phase 1 Clinical Trial Of [225Ac]-FPI-1434 Injection In Patients With Advanced Solid Tumors

BOSTON, Massachusetts and HAMILTON, Ontario—February 19, 2019 - Fusion Pharmaceuticals, a biopharmaceutical company focused on radiotherapeutics (specifically, targeted alpha therapeutics), today announced that the first patient was dosed in a Phase 1, first-in-human clinical trial of lead product candidate [225Ac]-FPI-1434 in patients with advanced solid tumors...

Inversago Pharma receives $7 million in series A financing

MONTREAL (CANADA) – 25 July 2018 – Today Inversago Pharma Inc. (“Inversago”) announced that it has secured a $7 million series A financing to pursue its development plan and advance its CB1 platform as a potent treatment for targeted diseases...

Neurological disorder biotech Aptinyx files for a $80 million IPO

May 23, 2018 – Aptinyx, which is developing therapeutics for neurological disorders, filed on Wednesday with the SEC to raise up to $80 million in an initial public offering...

Allergan Exercises Option to Acquire Compound from Aptinyx Discovery Platform Under Ongoing Research Collaboration

EVANSTON, IL – May 22, 2018 – Aptinyx Inc., a clinical-stage biopharmaceutical company developing transformative therapies for challenging neurologic disorders, today announced Allergan plc (NYSE: AGN) has exercised its option to acquire drug candidate AGN-241751, an oral small-molecule N-methyl-D-aspartate (NMDA) receptor modulator...

Initial Data from Profound Medical’s TACT Pivotal Clinical Trial Presented at AUA 2018

TORONTO, May 21, 2018 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX-V:PRN) (OTCQX:PRFMF) (“Profound” or the “Company”), the only company to provide a therapeutics platform that provides the precision of real-time Magnetic Resonance (“MR”) imaging combined with the safety and ablation power of directional and focused ultrasound technology...

Aptinyx Appoints Robert Hombach to Board of Directors

EVANSTON, IL., May 17, 2018 – Aptinyx Inc., a clinical-stage biopharmaceutical company developing transformative therapies for challenging neurologic disorders, today announced that it has appointed Robert J. Hombach, a healthcare industry veteran, to its board of directors.

Invitae Reports 169% Revenue Growth Driven by 150% Growth in Volume in First Quarter 2018

SAN FRANCISCO, May 9, 2018 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), one of the fastest growing genetics companies, today announced financial and operating results for the first quarter ended March 31, 2018. Based on the growing momentum in test volume and substantial revenue growth, the company is increasing its volume guidance...

Invitae Announces Pricing of Public Offering of Common Stock

SAN FRANCISCO, March 28, 2018 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA) today announced the pricing on March 27, 2018 of an underwritten public offering of 11,111,111 shares of its common stock at a price to the public of $4.50 per share. All of the shares are being sold by Invitae...

Profound Medical Corp. Upsizes Previously Announced Bought Deal Financing

MISSISSAUGA, ON, Feb. 28, 2018 /CNW/ - Profound Medical Corp. (TSXV:PRN) ("Profound" or the "Company") is pleased to announce today that it has entered into a revised agreement with a syndicate of underwriters, led by Canaccord Genuity Corp. (the "Underwriters"), pursuant to which the Underwriters will purchase, on a bought deal basis...

Invitae reports over 150% volume and over 170% revenue growth for 2017

SAN FRANCISCO, Feb. 12, 2018 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced financial and operating results for the fourth quarter and full year ended December 31, 2017.

Profound Medical Corp. Announces Completion of Patient Enrollment in TACT Pivotal Clinical Trial

TORONTO, Jan. 31, 2018 (GLOBE NEWSWIRE) -- Profound Medical Corp. today announced the completion of patient enrollment in the TACT (TULSA-PRO® Ablation Clinical Trial) pivotal study...pivotal study designed to further evaluate the safety and efficacy of TULSA-PRO® to ablate prostate tissue in patients with localized, organ-confined prostate cancer.

FloSonics Medical Secures $5 Million Seed Round Funding

SUDBURY ON — Jan. 29, 2018 — FloSonics Medical, a Canadian medical device company headquartered in Greater Sudbury, Ontario, has secured $5 million in a funding round led by Toronto’s iGan Partners. FloSonics Medical is focused on developing non-invasive sensors to improve the management of critically ill patients.

Adapsyn Bioscience Completes Financing to Advance its Small Molecule Natural Product Platform and Pipeline; Announces Research Collaboration with Pfizer Inc.

HAMILTON, ON, Jan. 9, 2018 /PRNewswire/ - Adapsyn Bioscience Inc., a biotechnology company focused on the discovery and development of novel medicines derived from evolved small molecule natural products, today announced that it has completed a round of financing...

Invitae more than doubles annual volume, exceeds full-year 2017 guidance, and projects momentum to continue in 2018

Jan. 8, 2018 - Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, announced preliminary full-year 2017 results that demonstrate continued strong momentum, with volume and revenue more than doubling compared to 2016 results. Preliminary financial results for 2017 include...

Profound Medical Corp. Announces Preliminary Fourth Quarter 2017 Revenue and Provides Progress Update on TACT Pivotal Trial Patient Enrollment

TORONTO, Jan. 08, 2018 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX-V:PRN) (OTCQX:PRFMF) (“Profound” or the “Company”), the only company to provide a therapeutics platform that provides the precision of real-time MR imaging combined with the safety and ablation power...

Aptinyx Raises $70 Million in Series B Financing to Advance Growing Pipeline through Clinical Studies in Neurologic Disorders

EVANSTON, Ill., Dec 18, 2017 /PRNewswire/-- Aptinyx Inc., a clinical-stage biopharmaceutical company developing transformative therapies for challenging neurologic disorders, today is announcing the completion of a $70 million Series B financing to fund advancement of its expanding clinical-stage pipeline...

Aptinyx Granted Fast Track Designation, Initiates Phase 1 for Second Clinical Candidate, NYX-783, in Post-Traumatic Stress Disorder

Evanston, Ill., Dec 7, 2017 – Aptinyx Inc., a clinical-stage biopharmaceutical company developing transformative therapies for challenging neurologic disorders, today announced Fast Track designation, new data, and initiation of Phase 1 clinical development for its second clinical candidate to modulate N-methyl-D-aspartate (NMDA) receptors, NYX-783, in post-traumatic stress disorder (PTSD). The data were presented at the annual meeting of the American College of Neuropsychopharmacology (ACNP)...

Fusion Pharmaceuticals completes a second closing of its Series A financing totaling $46 Million USD

HAMILTON, Ontario--(BUSINESS WIRE)--Fusion Pharmaceuticals, a clinical-stage biopharmaceutical company developing targeted alpha-particle radiotherapeutics for treating cancer, today announced it has completed a second closing of its Series A financing, securing an additional $21 million USD in capital and bringing the total capital raised to $46 million USD...

Siemens Healthineers to Acquire Epocal from Alere to Complete Its Blood Gas Portfolio

NORWOOD, Mass., July 21, 2017 (BUSINESS WIRE) Siemens Healthineers has entered into a definitive agreement to acquire Epocal Inc., a subsidiary of Alere Inc. Epocal Inc. develops and provides point-of-care blood diagnostic systems for healthcare enterprises, including the epoc® Blood Analysis System, a handheld, wireless testing solution. Financial details of the transaction are not being disclosed...

Fusion Pharmaceuticals Launches with a $25M USD Series A Financing to Develop Targeted Radiotherapeutics as Cancer Treat

HAMILTON, ON, February 23, 2017 - Fusion Pharmaceuticals, a newly formed biopharmaceutical company developing targeted alpha-particle radiotherapeutics for treating cancer, today announced the closing of a $25 million Series A financing led by founding venture investor, Johnson & Johnson Innovation - JJDC, Inc., with investments by HealthCap, TPG Biotech, Genesys Capital...

Profound Medical Announces Appointment of Kenneth Galbraith to its Board of Directors

TORONTO, Jan. 17, 2017 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX-V:PRN) ("Profound" or the "Company"), an emerging medical device company focused on prostate care, today announced the appointment of Kenneth Galbraith to its Board of Directors.

Invitae announces new leadership structure to drive global growth

January 09, 2017 - Invitae Corporation (https://www.invitae.com/en) (NYSE:NVTA), one of the fastest growing genetic information companies, today announced that Sean George, Ph.D., its co-founder and current president and chief operating officer, has been named chief executive officer for the company.

Invitae meets annual volume guidance, projects doubling of volume in 2017, accelerates Genome Network by acquiring scala

January 06, 2017 - Invitae Corporation (https://www.invitae.com/en) (NYSE:NVTA), one of the fastest growing genetic information companies, announced initial fourth quarter and full-year 2016 results, showing 200% year-over-year growth in billable test volume, driven by milestones including a major expansion of its test menu to more than 1,100 genes and agreements...

Invitae Announces Pricing of Public Offering of Common Stock

November 17, 2016 - SAN FRANCISCO -- (BUSINESS WIRE) -- Invitae Corporation (NYSE:NVTA) today announced the pricing of an underwritten public offering of 7,333,333 shares of its common stock at a price to the public of $6.00 per share.

Profound Medical Corp. Completes Previously Announced $17.4 Million Bought Deal Offering of Common Shares

TORONTO, Nov. 14, 2016 (GLOBE NEWSWIRE) -- Profound Medical Corp. ("Profound" or the "Company") (TSX-V:PRN) today announced that it has completed its previously announced bought deal offering of 15,820,000 common shares of the Company ("Common Shares") at a price of $1.10 per Common Share (the "Offering") for gross proceeds of...

Profound Medical Corp Announces First Patient Treated in TACT Pivotal Clinical Trial at Venderbilt University Medical Ce

TORONTO, Sept, 22, 2016 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSXV:PRN) ("Profound" or the "Company") a medical device company focused on prostate care, today announced that the first patient has been treated in the TACT Pivotal Clinical Trial at Vanderbilt University Medical Center in Nashville, TN.

Profound Medical Corp. Announces Senior Management Changes to Support Global Growth Strategy

TORONTO, Aug. 15, 2016 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSXV:PRN) ("Profound" or the "Company"), an emerging medical device company focused on prostate cancer care, today announced the appointment of Arun Menawat, Ph.D. as its new Chief Executive Officer.

Aptinyx Initiates Dosing in Phase 1 Clinical Study of Lead NMDA-Receptor Modulator, NYX-2925

Evanston, Ill., July 13, 2016 - Aptinyx Inc., a biopharmaceutical company developing novel modulators of the N-methyl-D-aspartate (NMDA) receptor for the treatment of challenging neurologic disorders, today announced the initiation of dosing in a Phase 1, first-in-human study for its lead therapeutic candidate, NYX 2925.

Profound Medical Corp. and Philips Sign Sales and Marketing Agreement in MRI-guided therapy for prostate cancer

TORONTO and AMSTERDAM, Netherlands, May 11, 2016 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSXV:PRN), a Toronto-based medical device company and Royal Philips (NYSE:PHG) (AEX:PHIA), a leading health technology company, today announced that they have signed a sales and marketing agreement that will advance the commercial launch of Profound's TULSA-PRO, a minimally...